argenex (ARGX) Stock Forecast & Price Target

$1,023.21 -35.69 (-3.37%)

As of 08/28/2026 04:00 PM Eastern

Compare

argenex - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
5

Buy
19

Based on 24 Wall Street analysts who have issued ratings for argenex in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 5 have given a hold rating, 17 have given a buy rating, and 2 have given a strong buy rating for ARGX.

Consensus Price Target

$1,157.50
13.12% Upside

According to the 24 analysts' twelve-month price targets for argenex, the average price target is $1,157.50. The highest price target for ARGX is $1,415.00, while the lowest price target for ARGX is $910.00. The average price target represents a forecasted upside of 13.12% from the current price of $1,023.21.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenex and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARGX Analyst Ratings Over Time

Type	Current Forecast 8/29/25 to 8/29/26	1 Month Ago 7/30/25 to 7/30/26	3 Months Ago 5/31/25 to 5/31/26	1 Year Ago 8/29/24 to 8/29/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	17 Buy rating(s)	18 Buy rating(s)	18 Buy rating(s)	19 Buy rating(s)
Hold	5 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$1,157.50	$1,056.89	$1,017.78	$766.50
Forecasted Upside	13.12% Upside	21.12% Upside	21.75% Upside	7.62% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

argenex Stock vs. The Competition

Type	argenex	Healthcare Companies	Broader Market
Consensus Rating Score	2.88	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	13.12% Upside	841.55% Upside	13.05% Upside
News Sentiment Rating	Neutral News See Recent ARGX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/26/2026	Wells Fargo & Company 3 of 5 stars	Derek Archila 5 of 5 stars	Boost Target	Overweight	$1,350.00 ➝ $1,415.00	+38.79%
8/26/2026	UBS Group 4 of 5 stars	Xian Deng Not Rated	Upgrade	Neutral ➝ Buy	$960.00 ➝ $1,400.00	+37.32%
8/24/2026	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Downgrade	Buy ➝ Hold
8/18/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,030.00 ➝ $1,095.00	+8.89%
8/18/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sean Laaman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,200.00 ➝ $1,230.00	+24.51%
8/18/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,025.00 ➝ $1,100.00	+11.35%
8/18/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Nierengarten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,050.00 ➝ $1,150.00	+16.42%
8/18/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason N. Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Outperform	$932.00 ➝ $1,200.00	+21.48%
8/18/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$940.00 ➝ $1,202.00	+21.68%
8/17/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allison Bratzel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,075.00 ➝ $1,215.00	+22.35%
A letter from Shannon Stansberry (Ad) Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. Watch the full story and see the verified track record for yourself
8/4/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yatin Suneja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$1,185.00	+40.36%
7/27/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Colleen Kusy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$867.00 ➝ $932.00	+1.50%
7/24/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leland Gershell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,014.00 ➝ $1,037.00	+13.55%
7/23/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold (C+) ➝ Hold (C)
7/21/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Samantha Semenkow Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,152.00 ➝ $1,182.00	+35.70%
7/2/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,016.00 ➝ $1,088.00	+14.60%
4/3/2026	Glj Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
2/20/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
12/19/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
12/11/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Thompson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,028.00 ➝ $1,248.00	+40.21%
12/8/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Gordon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$925.00 ➝ $1,100.00	+20.76%
11/24/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
10/31/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yaron Werber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$800.00 ➝ $1,146.00	+41.49%
10/31/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gavin Clark-Gartner Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$775.00 ➝ $910.00	+10.93%
8/26/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target	Buy	$818.00	+16.11%
3/17/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
2/28/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Myles Minter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
11/5/2024	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	George Farmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$439.00 ➝ $715.00	+21.46%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$605.00	+16.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:42 AM ET.

Should I Buy argenex Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, August 26, 2026. Please send any questions or comments about these argenex pros and cons to contact@marketbeat.com.

argenex
Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

The company recently reported strong earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial performance.
argenx SE has a high net margin, showcasing its efficiency in converting revenue into profit, which is attractive for potential investors.
With a market capitalization of approximately $63.78 billion, argenx SE is positioned as a major player in the biotechnology sector, suggesting stability and growth potential.
The current stock price is around $1,000, reflecting a strong market position and investor confidence in the company's future prospects.
Analysts have a consensus rating of "Moderate Buy" for argenx SE, with many recent upgrades to target prices, indicating positive sentiment in the market.

argenex
Bear Case

Investors should be bearish about investing in argenx SE for these reasons:

The stock has shown volatility, with a significant range between its one-year low and high, which may pose risks for conservative investors.
Despite strong earnings, the high P/E ratio suggests that the stock may be overvalued, which could lead to corrections in the future.
There is a substantial reliance on the success of its antibody-based therapeutics, which can be unpredictable and subject to regulatory challenges.
Recent institutional trading activity indicates mixed sentiment, with some investors significantly increasing their stakes while others may be cautious.
The biotechnology sector can be highly competitive and subject to rapid changes, which may impact argenx SE's market position and growth trajectory.

ARGX Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for argenex is $1,157.50, with a high forecast of $1,415.00 and a low forecast of $910.00.

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenex in the last year. There are currently 5 hold ratings, 17 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.

According to analysts, argenex's stock has a predicted upside of 13.12% based on their 12-month stock forecasts.

Over the previous 90 days, argenex's stock had 2 upgrades and 2 downgrades by analysts.

argenex has been rated by research analysts at Bank of America, Citigroup, Citizens Jmp, Deutsche Bank Aktiengesellschaft, Guggenheim, HC Wainwright, Morgan Stanley, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Truist Financial, UBS Group, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like argenex more than other "healthcare" companies. The consensus rating for argenex is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ARGX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With argenex Recommendations

MarketBeat monitors more than a dozen sources for argenex analyst ratings, with the most recent rating issued on 8/26/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenex (ARGX) Stock Forecast & Price Target

argenex - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ARGX Analyst Ratings Over Time

ARGX Analyst Recommendations By Month

ARGX Price Targets by Month

argenex Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy argenex Stock? ARGX Pros and Cons Explained

argenex
Bull Case

argenex
Bear Case

ARGX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With argenex Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

argenex (ARGX) Stock Forecast & Price Target

argenex - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ARGX Analyst Ratings Over Time

ARGX Analyst Recommendations By Month

ARGX Price Targets by Month

argenex Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy argenex Stock? ARGX Pros and Cons Explained

argenex Bull Case

argenex Bear Case

ARGX Forecast - Frequently Asked Questions

What is argenex's forecast for 2026?

Should I buy or sell argenex stock right now?

Does argenex's stock price have much upside?

Has argenex been upgraded or downgraded by Wall Street analysts recently?

What analysts cover argenex?

Do Wall Street analysts like argenex more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With argenex Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

argenex
Bull Case

argenex
Bear Case